A brave new framework for glioma drug development

Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns TC, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M (2024)

Publication Type: Journal article, Review article

Publication year: 2024

Journal

Book Volume: 25

Pages Range: e512-e519

Journal Issue: 10

DOI: 10.1016/S1470-2045(24)00190-6

Abstract

Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.

Authors with CRIS profile

Involved external institutions

Duke University Medical Center United States (USA) (US) Johns Hopkins Hospital United States (USA) (US) Erasmus University Medical Center (MC) Netherlands (NL) University of California Los Angeles (UCLA) United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Food and Drug Administration (FDA / USFDA) United States (USA) (US) Cleveland Clinic United States (USA) (US) Emory University United States (USA) (US) University of Sydney (USYD) Australia (AU) University of Glasgow United Kingdom (GB) Baptist Health South Florida United States (USA) (US) Northwestern University United States (USA) (US) Perelman School of Medicine University of Pennsylvania United States (USA) (US) University of Tokyo Japan (JP) Yale University United States (USA) (US) Vanderbilt University United States (USA) (US) University of California San Francisco (UCSF) United States (USA) (US) Mayo Clinic United States (USA) (US) University of Birmingham United Kingdom (GB) Barrow Neurological Institute United States (USA) (US) Medizinische Universität Wien Austria (AT) Ludwig-Maximilians-Universität (LMU) Germany (DE) Royal Melbourne Hospital (RMH) Australia (AU) Universitätsklinikum Mannheim Germany (DE) University of Toronto Canada (CA) National Brain Tumor Society (NBTS) United States (USA) (US) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) The University of Melbourne Australia (AU)

How to cite

APA:

Hotchkiss, K.M., Karschnia, P., Schreck, K.C., Geurts, M., Cloughesy, T.F., Huse, J.,... Khasraw, M. (2024). A brave new framework for glioma drug development. Lancet Oncology, 25(10), e512-e519. https://doi.org/10.1016/S1470-2045(24)00190-6

MLA:

Hotchkiss, Kelly M., et al. "A brave new framework for glioma drug development." Lancet Oncology 25.10 (2024): e512-e519.

BibTeX: Download